CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $240K into a new gene replacement…
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
…clinical trial for their investigational drug, NMD670, in patients with Charcot-Marie-Tooth disease (CMT). This trial, named SYNAPSE-CMT, marks a significant milestone in the journey towards finding effective treatments for CMT….
CMTA Announces New Center of Excellence in the United Kingdom
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease…
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
…gravis and Charcot-Marie-Tooth disease this year.” “As we witness groundbreaking advancements in the treatment of myasthenia gravis, we’re filled with hope for the potential translational impact on CMT,” said Katherine…
Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT) GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic…
2023 CMTA-STAR Celebrating our Collective Achievements
…2023, and led to an increasing number of treatments heading to clinical trials. Notably, Novartis acquired DTx Pharma’s CMT1A treatment and will move it forward into the clinic. The CMTA’s…
The Fall 2020 CMTA Report
…CMT Join Tribe of the Funky Feet Online CMT1A, CMT1B, CMT4B Projects Approved CMT1A Research Agenda Fuller than Ever 1A Timeline: CMTA Roadmap to Success Consensus Statement on Surgical Treatment…
Pharnext Premier PXT3003 for CMT1A Phase 3 Study
…for CMT1A, and treatment consists of supportive care such as orthoses, physical and occupational therapy or surgery. The purpose of the PREMIER study is to discover if PXT3003 is effective…
Cynthia Lawrence, Disney Princess and Athlete
…be very tiring … I know that there is currently no cure for CMT. That said, I want to always remain active and ready for a treatment when it comes,…
CMTA Centers of Excellence
CLINICAL EXPERTISE, COMPREHENSIVE EVALUATION AND CARE, INFORMATION CRUCIAL FOR CLINICAL TRIALS CMTA’s community-led, community-driven mission is to support the development of new treatments for Charcot-Marie-Tooth disease (CMT), to improve the…